Experimental Study Of C-erbb-2 And C-raf-1 Genes Antisense Oligodeoxynucleotides Combined Treatment In Ovarian Carcinoma

PART ONEOBJECTIVE: To investigate the proliferating inhibition and the mechanisms of c-erbB-2 and c-raf-1 genes antisense oligodeoxynucleotides combined transfection in the human ovarian carcinoma SKOV3 cell lines. METHODS: There were 7 groups in our study, normal control group, c-erbB-2 sense experimental group, c-raf-1 sense experimental group, c-erbB-2 antisense experimental group, c-raf-1 antisense experimental group, whole-dose experimental group, half-dose experimental group. In the different time after liposome-mediated transfection, the cell proliferation, apoptosis, mRNA level, protein expressing level and cell cycle were observed by MTT assay, flow cytometry, RT-PCR, electronic microscope, fluorescent microscope and cloning test. RESULTS: According to the results of whole-dose experimental group, half-dose experimental group, the OD-value were 0.151(p﹤0.005) and 0.073(p﹤0.005) transfectedafter 72h, the inhibitory rate of proliferation were 88.7% and 94.5%, the cloning efficiency were 19.4%(p﹤0.01)and 12.8%(p﹤0.01), the apoptosis rate were 24.3%(p﹤0.05)and 31.5%(p﹤0.01) and the level of mRNA and protein were decreased statistically in both c-erbB-2 and c-raf-1,respectively. CONCLUSIONS: These results suggested that c-erbB-2 and c-raf-1 combined ASODN is superior to single ASODN, and the half-dose group is more efficient than the whole-dose group in the treatment of ovarian carcinoma.KEY WORDS: SKOV3 cell lines; antisense oligodeoxynucleotides; combined transfection; ovarian carcinoma...